<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31491" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Anthracycline Medications (Doxorubicin)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Douedi</surname>
            <given-names>Steven</given-names>
          </name>
          <aff>Deborah Heart and Lung Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Carson</surname>
            <given-names>Michael P.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Steven Douedi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Carson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31491.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Doxorubicin is an anthracycline class medication used to manage and treat various types of malignancies and tumors. This activity will highlight the mechanism of action, adverse event profile, and other factors, including off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the mechanism of action of doxorubicin.</p></list-item><list-item><p>Identify the potential adverse reactions of doxorubicin.</p></list-item><list-item><p>Summarize the required monitoring of patients planning to take or currently taking doxorubicin.</p></list-item><list-item><p>Review the importance of collaboration and coordination among the interprofessional team to enhance outcomes for patients receiving chemotherapy with doxorubicin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31491&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31491">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31491.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Doxorubicin is an anthracycline class medication used to manage and treat various types of malignancies and tumors. It has both FDA-approved and off-label indications.<xref ref-type="bibr" rid="article-31491.r1">[1]</xref><xref ref-type="bibr" rid="article-31491.r2">[2]</xref></p>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute lymphocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Acute myelogenous leukemia</p>
          </list-item>
          <list-item>
            <p>Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Non-Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Bladder cancer</p>
          </list-item>
          <list-item>
            <p>Metastatic breast cancer</p>
          </list-item>
          <list-item>
            <p>Ewing sarcoma</p>
          </list-item>
          <list-item>
            <p>Metastatic neuroblastoma</p>
          </list-item>
          <list-item>
            <p>Metastatic ovarian carcinoma</p>
          </list-item>
          <list-item>
            <p>Metastatic osteogenic sarcoma</p>
          </list-item>
          <list-item>
            <p>Small cell lung cancer</p>
          </list-item>
          <list-item>
            <p>Metastatic soft tissue sarcoma</p>
          </list-item>
          <list-item>
            <p>Thyroid cancer</p>
          </list-item>
          <list-item>
            <p>Wilms tumor</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Advanced endometrial carcinoma</p>
          </list-item>
          <list-item>
            <p>Metastatic hepatocellular cancer</p>
          </list-item>
          <list-item>
            <p>Multiple myeloma</p>
          </list-item>
          <list-item>
            <p>Advanced renal cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Thymomas and thymic malignancies</p>
          </list-item>
          <list-item>
            <p>Uterine sarcoma</p>
          </list-item>
          <list-item>
            <p>Waldenstrom macroglobulinemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31491.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Doxorubicin is one of the cytotoxic anthracycline agents derived from <italic toggle="yes">Streptomyces spp.</italic>&#x000a0;The anthracycline class of agents has similar mechanisms of action and works by&#x000a0;intercalating&#x000a0;between the DNA base pairs causing uncoiling of the DNA helical structure. This action causes inhibition of DNA synthesis and affects the activity of DNA topoisomerase II.<xref ref-type="bibr" rid="article-31491.r3">[3]</xref>&#x000a0;Anthracyclines can also form free radicals, which can target and damage rapidly growing cells.<xref ref-type="bibr" rid="article-31491.r4">[4]</xref></p>
        <p>Doxorubicin is a major substrate of cytochrome P450, CYP3A4, CYP2D6, and P-glycoprotein (Pgp). Several clinically significant interactions have been reported with other inhibitors of CYP3A4, CYP2D6, and/or Pgp that can increase doxorubicin concentration, resulting in more or worsening side effects and toxicity at lower levels dosages.<xref ref-type="bibr" rid="article-31491.r4">[4]</xref></p>
      </sec>
      <sec id="article-31491.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Doxorubicin is available as a powder for injection or as a liquid solution [2 mg/mL] administered intravenously (IV) via a central line as a continuous infusion.<xref ref-type="bibr" rid="article-31491.r5">[5]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>60&#x000a0;to 75 mg/m^2 intravenously (IV) every 21 days OR</p>
          </list-item>
          <list-item>
            <p>60 mg/m2 IV every 14 days OR</p>
          </list-item>
          <list-item>
            <p>40 to 60 mg/m^2 IV every 21&#x000a0;to 28 days OR</p>
          </list-item>
          <list-item>
            <p>20 mg/m^2/dose once/week</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>35 to 75 mg/m^2 intravenously (IV) every 21 days&#x000a0;</p>
          </list-item>
          <list-item>
            <p>20 to 30 mg/m^2/dose once/week</p>
          </list-item>
          <list-item>
            <p>60 to 90 mg/m^2 IV over 96 hours every 3&#x000a0;to 4 weeks</p>
          </list-item>
        </list>
        <p>
<bold>Renal Impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No dosage adjustment is necessary</p>
          </list-item>
        </list>
        <p>
<bold>Hepatic Impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Total serum bilirubin&#x000a0;less than 1.2 mg/dL: No dosage adjustment is necessary</p>
          </list-item>
          <list-item>
            <p>Total serum bilirubin 1.2&#x000a0;to 3.0 mg/dL: Decrease dose by 50%</p>
          </list-item>
          <list-item>
            <p>Total serum bilirubin: 3.1&#x000a0;to 5.0 mg/dL: Decrease dose by 25%</p>
          </list-item>
          <list-item>
            <p>Severe hepatic impairment: Contraindicated due to toxicity</p>
          </list-item>
        </list>
        <p>Due to the side effect profile and toxicity of doxorubicin, patients are only allowed a lifetime dose of 550 mg/m^2.&#x000a0;Patients receiving&#x000a0;doxorubicin therapy must receive close follow-up and monitoring of blood counts, liver function, and heart function studies.<xref ref-type="bibr" rid="article-31491.r6">[6]</xref></p>
      </sec>
      <sec id="article-31491.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Side Effects</bold>
<xref ref-type="bibr" rid="article-31491.r7">[7]</xref>
<xref ref-type="bibr" rid="article-31491.r8">[8]</xref>
<xref ref-type="bibr" rid="article-31491.r9">[9]</xref>
<xref ref-type="bibr" rid="article-31491.r10">[10]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic reactions (anaphylaxis)</p>
          </list-item>
          <list-item>
            <p>Severe cough</p>
          </list-item>
          <list-item>
            <p>Photosensitivity</p>
          </list-item>
          <list-item>
            <p>Skin and nail hyperpigmentation</p>
          </list-item>
          <list-item>
            <p>Hoarseness of voice</p>
          </list-item>
          <list-item>
            <p>Flushing of the face</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Joint pain</p>
          </list-item>
          <list-item>
            <p>Painful or difficult urination</p>
          </list-item>
          <list-item>
            <p>Persistent diarrhea</p>
          </list-item>
        </list>
        <p>
<bold>Less Common Side Effects</bold>
<xref ref-type="bibr" rid="article-31491.r4">[4]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Black/tarry or bloody stools</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Tissue necrosis or death</p>
          </list-item>
          <list-item>
            <p>Cardiac arrhythmias</p>
          </list-item>
          <list-item>
            <p>Anemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Neutropenia</p>
          </list-item>
          <list-item>
            <p>Shortness of breath due to congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Edema in ankles or feet due to congestive heart failure</p>
          </list-item>
          <list-item>
            <p>A decrease in left-ventricular ejection fraction (LVEF) of greater than or equal to 10%&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Tumor lysis syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31491.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Previous allergic reaction or anaphylaxis</p>
          </list-item>
          <list-item>
            <p>Pregnancy or if planning to become pregnant (relative contraindication&#x000a0;- should be used for cancer treatment during pregnancy when indicated as a first-line agent)</p>
          </list-item>
          <list-item>
            <p>Current active viral or bacterial infections</p>
          </list-item>
          <list-item>
            <p>Severe hepatic impairment and/or total serum bilirubin&#x000a0;over 5.0 mg/dL</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction within the last 30 days before treatment</p>
          </list-item>
          <list-item>
            <p>Prior treatment to a maximum dose of 550 mg/m^2 with doxorubicin or other anthracycline agents</p>
          </list-item>
          <list-item>
            <p>Systolic dysfunction/cardiomyopathy not optimized on medical therapy</p>
          </list-item>
          <list-item>
            <p>Intramuscular or subcutaneous administration</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31491.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Due to the cardiotoxic profile of doxorubicin, baseline left ventricular ejection fraction (LVEF) should be assessed and monitored routinely using an echocardiogram. An LVEF drop of greater than 10% from baseline is considered indicative of cardiotoxicity, and immediate intervention by physicians and the healthcare team is required. An alternative to echocardiogram monitoring is radionuclide ventriculography, such as multi-gated acquisition angiogram (MUGA) or equilibrium radionuclide angiogram (ERNA) scans, although less frequently used.<xref ref-type="bibr" rid="article-31491.r4">[4]</xref><xref ref-type="bibr" rid="article-31491.r11">[11]</xref></p>
        <p>Obtain baseline complete blood counts (CBC), hepatic enzymes, and tests of hepatic function.</p>
      </sec>
      <sec id="article-31491.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The most prevalent toxicities appear below, as reported by several case studies and medication trials.<xref ref-type="bibr" rid="article-31491.r12">[12]</xref><xref ref-type="bibr" rid="article-31491.r13">[13]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiomyopathy/cardiotoxicity: The incidence of myocardial damage from doxorubicin ranges from 1% to 20%, with dosages above 300 mg/m2. LVEF is important to monitor before, during, and after doxorubicin treatment.<xref ref-type="bibr" rid="article-31491.r4">[4]</xref><xref ref-type="bibr" rid="article-31491.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Secondary malignancies: Although used to treat various malignancies and tumors, doxorubicin and other anthracyclines are known for causing secondary malignancies such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).</p>
          </list-item>
          <list-item>
            <p>Tissue necrosis: doxorubicin extravasation can cause severe tissue death and necrosis requiring excision and grafting of the skin. It is important to monitor during intravenous injection or infusion of the agent.</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity: Hepatic failure is a strong contraindication to the use of doxorubicin. Trending total bilirubin concentrations and monitoring liver enzyme concentrations is essential.</p>
          </list-item>
          <list-item>
            <p>Myelosuppression: As with other anthracyclines, doxorubicin is known for causing severe myelosuppression requiring routine monitoring of white blood counts, hemoglobin, and platelets as myelosuppression predisposes to infections, sepsis, hospitalizations, or even death.</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Toxicity Prevention</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Several pharmacological agents have been used and studied to prevent and/or decrease cardiotoxicity in patients receiving anthracyclines, including dexrazoxane, beta-blockers, angiotensin antagonists, statins coenzyme Q-10, and N-acetylcysteine. Most notable studies have taken place testing beta-blockers and dexrazoxane.</p>
          </list-item>
          <list-item>
            <p>In one randomized study of 25 patients, carvedilol was not better than a placebo at preventing systolic and diastolic heart failure in patients taking anthracyclines.<xref ref-type="bibr" rid="article-31491.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Dexrazoxane is a prodrug and potent reversible inhibitor of DNA topoisomerase II, which may decrease topoisomerase II binding by doxorubicin and thus decrease the cytotoxicity of healthy cells. Dexrazoxane is an iron chelator (structurally similar to EDTA) that is thought to decrease free radicals generated by doxorubicin.</p>
          </list-item>
          <list-item>
            <p>A retrospective study found that&#x000a0;dexrazoxane&#x000a0;did not significantly affect the mean LVEF after anthracycline administration (56% with dexrazoxane vs. 53% without), but while&#x000a0;the authors concluded that it decreased the&#x000a0;rate of cardiac events, defined as a reduction of LVEF&#x000a0;more than 10%, it is difficult&#x000a0;to reconcile that conclusion of this retrospective analysis with the fact that the mean LVEF between the two groups was not different.<xref ref-type="bibr" rid="article-31491.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>In a meta-analysis reviewing 16 trials, including 1918 patients: dexrazoxane reduced cardiotoxicity after anthracycline treatment by 33%. It specifically decreased heart failure by 58% compared to other agents, including beta-blockers, statins, coenzyme Q-10, and N-acetylcysteine. However, the study determined&#x000a0;dexrazoxane did not affect the response rate of malignancies or the risk of death.<xref ref-type="bibr" rid="article-31491.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Further studies are in process and have begun to attract attention to minimize the cardiotoxicity risk of doxorubicin.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31491.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Doxorubicin has been a mainstay in treating various cancers for many years, and members of the interprofessional health care team must be aware and up to date on the indications, interaction, adverse effects, and other pharmacodynamic and pharmacokinetic factors that can affect successful therapy implementation, and lead to improved patient outcomes.&#x000a0;</p>
        <p>Prescribing and monitoring doxorubicin requires an interprofessional team of healthcare professionals that includes clinicians (MDs, DOs, NPs, PAs), various specialists (e.g., cardiologist, and hematologist/oncologist), nursing staff with specialized oncology and chemotherapy training, laboratory technologists, and pharmacists (preferably also oncology specialized)all working collaboratively and engaging in open communication about the patient's progress, status, and response to treatment.</p>
        <p>Proper monitoring for complications, particularly cardiac and hepatic, is indicated as a retrospective study reported cardiotoxicity in 26%, and the 1-year mortality with doxorubicin-induced cardiotoxicity is as high as 50%.<xref ref-type="bibr" rid="article-31491.r18">[18]</xref><xref ref-type="bibr" rid="article-31491.r19">[19]</xref>&#x000a0;Research has also shown cardiotoxicity as the leading cause of death in patients taking anthracyclines, as seen by several extensive randomized clinical retrospective studies.<xref ref-type="bibr" rid="article-31491.r4">[4]</xref> [Level 1]&#x000a0;</p>
        <p>Regularly monitor complete blood counts and metabolic panels to monitor for myelosuppression. The medical team should respond and assess significant changes to consider halting the drug when indicated. This monitoring function often falls to the clinical pharmacist, who will track the necessary lab work and inform the ordering clinician regarding situations that require alterations in the regimen. Nursing will be well versed in administration and monitoring for side effects, particularly extravasation, and inform the team of any concerns.</p>
        <p>Team coordination is also necessary when considering&#x000a0;using dexrazoxane to decrease the risk of cardiotoxicity.&#x000a0;</p>
        <p>This interprofessional paradigm leads to the best patient result for&#x000a0;oncological care with doxorubicin while mitigating risks and preventing adverse events. [Level 5]</p>
      </sec>
      <sec id="article-31491.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31491&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31491">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31491/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31491">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31491.s11">
        <title>References</title>
        <ref id="article-31491.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seetharam</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>First-Line Therapy for Metastatic Soft Tissue Sarcoma.</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>24</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">30675651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meg&#x000ed;as-Vericat</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Cuadr&#x000f3;n</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
              <name>
                <surname>Poveda</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Montesinos</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>197</fpage>
            <page-range>197-218</page-range>
            <pub-id pub-id-type="pmid">30672340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <chapter-title>Cytotoxic Antibiotics</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGowan</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maulik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piotrowska</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yellon</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Anthracycline Chemotherapy and Cardiotoxicity.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-75</page-range>
            <pub-id pub-id-type="pmid">28185035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <chapter-title>Doxorubicin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">31643934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franco</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Ait-Oudhia</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer.</article-title>
            <source>Breast Cancer (Dove Med Press)</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>131</fpage>
            <page-range>131-141</page-range>
            <pub-id pub-id-type="pmid">30237735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tahara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hane</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sasaoka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hatahira</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Motooka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naganuma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nakao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>e0185654</fpage>
            <pub-id pub-id-type="pmid">28953936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <chapter-title>Antineoplastic Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31643354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oelze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nzel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Daiber</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The anti-cancer drug doxorubicin induces substantial epigenetic changes in cultured cardiomyocytes.</article-title>
            <source>Chem Biol Interact</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>313</volume>
            <fpage>108834</fpage>
            <pub-id pub-id-type="pmid">31545955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pituskin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haykowsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McNeely</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).</article-title>
            <source>BMC Cancer</source>
            <year>2016</year>
            <month>Sep</month>
            <day>15</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>733</fpage>
            <pub-id pub-id-type="pmid">27629548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Monitoring cardiac function in patients receiving doxorubicin.</article-title>
            <source>Semin Nucl Med</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>197</fpage>
            <page-range>197-201</page-range>
            <pub-id pub-id-type="pmid">16098293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorn</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Oshiro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hernandez-Boussard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Doxorubicin pathways: pharmacodynamics and adverse effects.</article-title>
            <source>Pharmacogenet Genomics</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>440</fpage>
            <page-range>440-6</page-range>
            <pub-id pub-id-type="pmid">21048526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pugazhendhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edison</surname>
                <given-names>TNJI</given-names>
              </name>
              <name>
                <surname>Velmurugan</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Karuppusamy</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of Doxorubicin (Dox) to different experimental organ systems.</article-title>
            <source>Life Sci</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>200</volume>
            <fpage>26</fpage>
            <page-range>26-30</page-range>
            <pub-id pub-id-type="pmid">29534993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatterjee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Honbo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Karliner</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Doxorubicin cardiomyopathy.</article-title>
            <source>Cardiology</source>
            <year>2010</year>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-62</page-range>
            <pub-id pub-id-type="pmid">20016174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalay</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Basar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ozdogru</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Er</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cetinkaya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Inanc</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oguzhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eryol</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Topsakal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ergin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Protective effects of carvedilol against anthracycline-induced cardiomyopathy.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2006</year>
            <month>Dec</month>
            <day>05</day>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>2258</fpage>
            <page-range>2258-62</page-range>
            <pub-id pub-id-type="pmid">17161256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Youn</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab.</article-title>
            <source>J Breast Cancer</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <page-range>82-90</page-range>
            <pub-id pub-id-type="pmid">28382098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Qadir</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fazelzad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amir</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Thavendiranathan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.</article-title>
            <source>Ann Oncol</source>
            <year>2017</year>
            <month>Mar</month>
            <day>01</day>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>628</fpage>
            <page-range>628-633</page-range>
            <pub-id pub-id-type="pmid">28028033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swain</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Whaley</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Ewer</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.</article-title>
            <source>Cancer</source>
            <year>2003</year>
            <month>Jun</month>
            <day>01</day>
            <volume>97</volume>
            <issue>11</issue>
            <fpage>2869</fpage>
            <page-range>2869-79</page-range>
            <pub-id pub-id-type="pmid">12767102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31491.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oikonomou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Anastasiou</surname>
                <given-names>&#x0039c;</given-names>
              </name>
              <name>
                <surname>Siasos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Androulakis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Psyrri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toutouzas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tousoulis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment.</article-title>
            <source>Curr Pharm Des</source>
            <year>2018</year>
            <volume>24</volume>
            <issue>37</issue>
            <fpage>4424</fpage>
            <page-range>4424-4435</page-range>
            <pub-id pub-id-type="pmid">30636595</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
